Olema Oncology, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, has completed an $85 million Series C financing. Olema will use the financing proceeds to advance the clinical development of OP-1250, its lead product candidate in breast cancer, and expand ongoing research and development activities.   OP-125  is currently being evaluated in a Phase 1/2 clinical trial in patients with recurrent,...